热门资讯> 正文

InflaRx股价突破1美元后重新合规

2026-04-28 19:53

InflaRx N.V. on Tuesday said it had regained compliance with Nasdaq’s minimum bid price requirement, after its shares closed at or above $1.00 for 10 consecutive business days between April 13 and April 24.
The company received written confirmation from Nasdaq on April 27 that the matter has been resolved and is now closed.
InflaRx develops anti-inflammatory therapies targeting the complement system, with lead programs including izicopan and vilobelimab currently in clinical development.

More on InflaRx

InflaRx N.V. (IFRX) Presents at Oppenheimer 36th Annual Healthcare Life Sciences Conference - Slideshow
InflaRx receives Nasdaq notification
Seeking Alpha’s Quant Rating on InflaRx
Historical earnings data for InflaRx
Financial information for InflaRx

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。